Guardant Health, Inc. (GH)
NASDAQ: GH · Real-Time Price · USD
86.40
+4.19 (5.10%)
At close: Apr 14, 2026, 4:00 PM EDT
86.40
0.00 (0.00%)
After-hours: Apr 14, 2026, 4:40 PM EDT
Guardant Health Employees
As of December 31, 2025, Guardant Health had 2,506 total employees, including 2,490 full-time and 16 part-time employees. The number of employees increased by 485 or 24.00% compared to the previous year.
Employees
2,506
Change (1Y)
485
Growth (1Y)
24.00%
Revenue / Employee
$391,868
Profits / Employee
-$166,112
Market Cap
11.33B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 2,506 | 485 | 24.00% | 2,490 | 16 |
| Dec 31, 2024 | 2,021 | 242 | 13.60% | 1,999 | 22 |
| Dec 31, 2023 | 1,779 | -14 | -0.78% | 1,768 | 11 |
| Dec 31, 2022 | 1,793 | 420 | 30.59% | 1,793 | 0 |
| Dec 31, 2021 | 1,373 | 509 | 58.91% | 1,373 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Labcorp Holdings | 71,000 |
| Quest Diagnostics | 57,000 |
| ICON Public Limited Company | 41,900 |
| Charles River Laboratories International | 19,700 |
| Mettler-Toledo International | 18,100 |
| Revvity | 11,000 |
| Illumina | 10,080 |
| RadNet | 9,276 |
GH News
- 15 days ago - Guardant Health's InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan - Business Wire
- 21 days ago - Verana Health and Guardant Health Partner to Advance Precision Medicine with Real-World Data - PRNewsWire
- 27 days ago - Guardant Health to Present 28 Abstracts Highlighting Advances in Tumor Typing, Therapy Selection and Expanded Utility of Multiomic Tissue and Liquid Biopsy Testing at AACR 2026 - Business Wire
- 4 weeks ago - Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership - Business Wire
- 4 weeks ago - New Guardant Health/Harris Poll Survey Shows 92% of All Eligible Americans Believe Colorectal Cancer Blood Tests Should be Accessible and Covered Similar to Medicare - Business Wire
- 5 weeks ago - Guardant Health's Shield Blood-based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics - Business Wire
- 5 weeks ago - Guardant Health Launches Coast-to-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to Over 100 Communities Across America - Business Wire
- 6 weeks ago - Actor and Cancer Advocate Patrick Dempsey Partners with Guardant Health to Raise Awareness about Colorectal Cancer Screening and Shield Blood Test, Sharing His Experience Getting Screened - Business Wire